Soligenix Inc. (SNGX) Posts Quarterly Earnings Results, Beats Estimates By $0.15 EPS
Soligenix Inc. (NASDAQ:SNGX) posted its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.32) by $0.15, Bloomberg Earnings reports. Soligenix had a negative net margin of 86.15% and a negative return on equity of 129.88%. The company had revenue of $1.82 million during the quarter, compared to analyst estimates of $1.36 million.
Soligenix (NASDAQ SNGX) opened at $2.00 on Tuesday. Soligenix has a 52-week low of $1.74 and a 52-week high of $5.08.
Several research analysts have commented on SNGX shares. HC Wainwright reiterated a “buy” rating and issued a $5.50 target price (down from $11.00) on shares of Soligenix in a report on Monday. Maxim Group set a $5.00 price target on shares of Soligenix and gave the stock a “buy” rating in a research report on Tuesday, October 31st.
TRADEMARK VIOLATION WARNING: “Soligenix Inc. (SNGX) Posts Quarterly Earnings Results, Beats Estimates By $0.15 EPS” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://www.watchlistnews.com/soligenix-inc-sngx-posts-quarterly-earnings-results-beats-estimates-by-0-15-eps/1684910.html.
Soligenix, Inc is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.
Receive News & Ratings for Soligenix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.